5 Key Takeaways

• 1

  The Stockholm3 test significantly reduced MRI scans in prostate cancer screening by refining patient selection based on PSA levels.

• 2

  In the study, MRI use fell from 2.7% to 1.1%, representing a 60% relative reduction in the experimental cohort.

• 3

  Biopsy rates also declined from 0.6% to 0.4% with the introduction of the Stockholm3 test in the screening process.

• 4

  Cancer detection rates were similar, with clinically significant cancers detected in fewer men in the Stockholm3 group.

• 5

  The study demonstrates the potential of multi-marker blood tests to optimize prostate cancer screening and reduce unnecessary procedures.